Giorgio Ghilardi

Prof. Dr. Giorgio Ghilardi

Department of Health Sciences, Università degli Studi di Milano, 20122 Milan, Italy
orcid

Research Focus & Metrics

Academic Career Length

34Years (1993-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2016 in Cancer Research
Verified
Journal Article
Closed access
PDF file
ELElisa Latorre
Elisa Latorre
SCStephana Carelli
Stephana Carelli
IRIvan Raimondi
Ivan Raimondi
VDVito Giuseppe D'Agostino
Vito Giuseppe D'Agostino
ICIlaria Castiglioni
Ilaria Castiglioni
APAlessandro Provenzani
Alessandro Provenzani
Epithelial-to-mesenchymal transition (EMT) is a core process underlying cell movement during embryonic development and morphogenesis. Cancer cells hijack this developmental program to execute a multi-step cascade, leading to tumorigenesis and metastasis. CD133 (PROM1), a marker of cancer stem cells, has been shown to facilitate EMT in various cancers, but the regulatory networks controlling CD133 gene expression and function in cancer remain incompletely delineated. In this study, we show that a ribonucleoprotein complex including the long noncoding RNA MALAT1 and the RNA-binding protein HuR (ELAVL1) binds the CD133 promoter region to regulate its expression. In luminal nonmetastatic MCF-7 breast cancer cells, HuR silencing was sufficient to upregulate N-cadherin (CDH2) and CD133 along with a migratory and mesenchymal-like phenotype. Furthermore, we found that in the basal-like metastatic cell line MDA-MB-231 and primary triple-negative breast cancer tumor cells, the repressor complex was absent from the CD133-regulatory region, but was present in the MCF-7 and primary ER+ tumor cells. The absence of the complex from basal-like cells was attributed to diminished expression of MALAT1, which, when overexpressed, dampened CD133 levels. In conclusion, our findings suggest that the failure of a repressive complex to form or stabilize in breast cancer promotes CD133 upregulation and an EMT-like program, providing new mechanistic insights underlying the control of prometastatic processes. Cancer Res; 76(9); 1–11. ©2016 AACR.

1 October 2002 in Stroke
Verified
Journal Article
Closed access
PDF file
GGGiorgio Ghilardi
Giorgio Ghilardi
MBMaria Luisa Biondi
Maria Luisa Biondi
MDMarco DeMonti
Marco DeMonti
OTOlivia Turri
Olivia Turri
EGEmma Guagnellini
Emma Guagnellini
RSRoberto Scorza
Roberto Scorza
Background and Purpose— The matrix metalloproteinases (MMPs) are a family of enzymes that are important in the resorption of extracellular matrix and are involved in atherogenesis. Recently, 2 common polymorphisms on MMP-1 (1G/2G) and MMP-3 (5A/6A) gene promoters have been described. The aim of this study was to investigate a possible association between MMP polymorphisms and increased risk of internal carotid artery (ICA) stenosis. Methods— We studied 91 patients consecutively recruited for ICA stenosis who had undergone carotid endarterectomy and 133 subjects without ICA stenosis (controls). Polymorphic genotypes were determined by polymerase chain reaction and sequencing analysis. Results— The frequency of the 6A allele was significantly different between cases and controls: 0.62 and 0.50, respectively (odds ratio [OR], 1.58; 95% CI, 1.08 to 2.33; P =0.017). The frequency of 6A/6A genotype was significantly higher in cases with involvement of both carotids (OR, 3.13; 95% CI, 1.14 to 8.5; P =0.026) and in patients with stenosis >70% (OR, 2.55; 95% CI, 1.07 to 6.07; P =0.033). No significant differences were observed in MMP-1 distribution. Patients who were homozygous for both the 6A and 2G alleles had an elevated relative risk of ICA stenosis (OR, 2.66; 95% CI, 1.23 to 5.72; P =0.016). Multiple logistic regression analysis using the common risk factors and the 6A and 2G allele variants revealed that the 6A allele was an independent risk factor for ICA stenosis ( P =0.049). When 6A/6A and 2G/2G were combined, the risk factor for ICA stenosis was 3-fold higher (OR, 3.31; 95% CI, 1.48 to 7.42; P =0.004). Conclusions— Homozygosity for the 6A allele of the MMP-3 promoter is associated with carotid stenosis and, in association with MMP-1 2G homozygosity, predicts an increased risk of ICA stenosis. Even if obtained from a relatively limited patient series, these results might have relevant implications for treatment of ICA stenosis and possibly prevention of carotid-related stroke.

21 April 2006 in Gut
Verified
Journal Article
Closed access
PDF file
MAM Allocca
M Allocca
ACA Crosignani
A Crosignani
AGA Gritti
A Gritti
GGGiorgio Ghilardi
Giorgio Ghilardi
DGD Gobatti
D Gobatti
PBP M Battezzati
P M Battezzati
Background: Hypercholesterolaemia often occurs in primary biliary cirrhosis (PBC) as a result of chronic cholestasis, but whether these patients are exposed to greater cardiovascular risk is unknown. Aim: To establish whether hypercholesterolaemia is associated with subclinical atherosclerosis in PBC. Patients: 103 consecutive patients with PBC (37 with total cholesterol ⩾6.21 mmol/l) and 37 controls with hypercholesterolaemia, and 141 matched controls with normocholesterolaemia. Methods: Ultrasound imaging of carotid artery to determine intima–media thickness (IMT) and stenosis. Results: Controls with hypercholesterolaemia had higher IMT and prevalence of carotid stenosis compared with patients with hypercholesterolaemic PBC (mean (SD) 0.850 (0.292) mm v 0.616 (0.137) mm, pc<0.001; 43% v 19%, pc = 0.129) who, in turn, were similar to the 66 patients with normocholesterolaemic PBC (0.600 (0.136) mm; 5%). Compared with subjects with normocholesterolaemia, controls with hypercholesterolaemia, but not patients with hypercholesterolaemic PBC, had an increased risk of raised IMT (odds ratio (OR) 5.4, 95% confidence interval (CI) 2.5 to 11.9, p<0.001; and 0.7, 0.3 to 2.0, p = 0.543) or carotid stenosis (8.2, 3.4 to 20, p<0.001; and 2.5, 0.9 to 6.9, p = 0.075). In PBC, compared with younger patients without hypertension, the risk of increased IMT was OR (CI) 3.1 (0.6 to 17; p = 0.192) in patients with hypertension or old age, but not hypercholesterolaemia, and 4.6 (0.8 to 27; p = 0.096) in patients who also had hypercholesterolaemia. The corresponding figures for risk of stenosis were 3.6 (0.4 to 36; p = 0.277) and 15.8 (1.8 to 141; p = 0.014). Conclusions: Hypercholesterolaemia is not consistently associated with subclinical atherosclerosis in PBC, but should be treated if other risk factors for cardiovascular disease are also present. The search for factors that may protect patients with hypercholesterolaemic PBC against atherosclerosis should be encouraged.

1 February 2005 in Clinical Chemistry
Verified
Journal Article
Closed access
PDF file
GGGiorgio Ghilardi
Giorgio Ghilardi
MBMaria Luisa Biondi
Maria Luisa Biondi
ATAnna La Torre
Anna La Torre
LBLodovica Battaglioli
Lodovica Battaglioli
RSRoberto Scorza
Roberto Scorza

1 July 2002 in Clinical Chemistry
Verified
Journal Article
Open access
PDF file
GGGiorgio Ghilardi
Giorgio Ghilardi
MBMaria Luisa Biondi
Maria Luisa Biondi
MDMarco DeMonti
Marco DeMonti
MBMara Bernini
Mara Bernini
OTOlivia Turri
Olivia Turri
RSRoberto Scorza
Roberto Scorza
Background: NO synthesized from l-arginine by the constitutive endothelial NO synthase (eNOS) plays a key role in the atherosclerotic process. We investigated whether common variants in the NOS3 gene (a T786C mutation in the 5′ flanking region and the polymorphism on exon 7 that produced the Glu298Arg polymorphism in the protein) are associated with an increased risk of moderate to severe internal carotid artery (ICA) stenosis. Methods: We studied 88 patients consecutively operated for ICA stenosis and 133 healthy controls. A T786C mutation in the 5′ flanking region and the polymorphism in exon 7 that produces the Glu298Asp polymorphism in the protein were explored by PCR and fluorescent probe analysis. Results: Genotype distribution was significantly different between patients and controls only for T786C, the CC genotype frequency being 26% and 13%, respectively [odds ratio (OR), 2.26; 95% confidence interval (CI), 1.14–4.46; P = 0.018]. Moreover, the CC genotype was significantly more frequent in a subgroup of patients with ulcerative plaques compared with patients with nonulcerative lesions (44% vs 17%; OR, 3.82; 95% CI, 1.79–8.14; P = 0.003). Multiple logistic regression analysis using the most frequent risk factors and the eNOS gene variant showed that the CC genotype is an independent risk factor for ICA stenosis (P = 0.023). Conclusion: C allele homozygosity in position 786 of the eNOS promoter seems to be an independent risk factor for the development of moderate to severe ICA stenosis, especially ulcerative lesions.

1 November 2003 in Clinical Chemistry
Verified
Journal Article
Closed access
GGGiorgio Ghilardi
Giorgio Ghilardi
MBMaria Luisa Biondi
Maria Luisa Biondi
MEMaddalena Erario
Maddalena Erario
EGEmma Guagnellini
Emma Guagnellini
RSRoberto Scorza
Roberto Scorza